Mckinley Capital Management LLC Delaware reduced its stake in shares of Celgene Corporation (NASDAQ:CELG) by 0.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 43,992 shares of the biopharmaceutical company’s stock after selling 48 shares during the period. Mckinley Capital Management LLC Delaware’s holdings in Celgene Corporation were worth $5,474,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of CELG. Harvey Capital Management Inc. boosted its position in Celgene Corporation by 1.0% in the first quarter. Harvey Capital Management Inc. now owns 65,000 shares of the biopharmaceutical company’s stock valued at $8,087,000 after buying an additional 620 shares in the last quarter. Reilly Financial Advisors LLC boosted its position in Celgene Corporation by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 161 shares in the last quarter. Howland Capital Management LLC boosted its position in Celgene Corporation by 30.5% in the first quarter. Howland Capital Management LLC now owns 137,716 shares of the biopharmaceutical company’s stock valued at $17,136,000 after buying an additional 32,188 shares in the last quarter. Washington Trust Bank boosted its position in Celgene Corporation by 1.3% in the first quarter. Washington Trust Bank now owns 3,613 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 46 shares in the last quarter. Finally, Howe & Rusling Inc. boosted its position in Celgene Corporation by 308,050.0% in the first quarter. Howe & Rusling Inc. now owns 30,815 shares of the biopharmaceutical company’s stock valued at $3,834,000 after buying an additional 30,805 shares in the last quarter. 79.43% of the stock is currently owned by institutional investors.

Celgene Corporation (NASDAQ:CELG) traded up 1.582% on Wednesday, reaching $134.535. 856,713 shares of the company’s stock were exchanged. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00. The firm’s 50-day moving average is $133.39 and its 200-day moving average is $125.39. The firm has a market cap of $105.25 billion, a PE ratio of 41.665 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.44 earnings per share. On average, equities analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Mckinley Capital Management LLC Delaware Lowers Position in Celgene Corporation (CELG)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/30/mckinley-capital-management-llc-delaware-lowers-position-in-celgene-corporation-celg.html.

Several research analysts have issued reports on the company. Mizuho set a $134.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 27th. Robert W. Baird reaffirmed an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a report on Friday, July 21st. Jefferies Group LLC reaffirmed a “buy” rating and issued a $160.00 price target on shares of Celgene Corporation in a report on Monday, July 31st. Finally, Cann reaffirmed a “buy” rating and issued a $175.00 price target on shares of Celgene Corporation in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $147.38.

In other Celgene Corporation news, Director Michael D. Casey sold 9,250 shares of the stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $125.59, for a total transaction of $1,161,707.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ernest Mario sold 18,506 shares of the stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 253,761 shares of company stock valued at $33,792,445. 0.95% of the stock is owned by company insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.